FTV:NYSEFortive Corporation Analysis
Data as of 2026-09-05 - not real-time
$56.94
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
At $56.94, Fortive Corporation shows no decisive moving-average alignment, leaving the trend neutral. It has lost 8.6% over the past 30 days. With RSI at 36.6 the momentum picture is approaching oversold, alongside a bearish MACD signal. Recent trading has carved out support near $56.12 and resistance around $62.62.
On valuation the read is fair — earnings multiple of 30.4 versus a 33.2 sector average, in line with the peer group. Analyst price targets sit 12.9% above the current price. Revenue is growing at 7.9% on a 12.4% profit margin. The 0.49% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 29.7%, a beta of 0.64 and a maximum drawdown of 13.4%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 3/10.
On valuation the read is fair — earnings multiple of 30.4 versus a 33.2 sector average, in line with the peer group. Analyst price targets sit 12.9% above the current price. Revenue is growing at 7.9% on a 12.4% profit margin. The 0.49% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 29.7%, a beta of 0.64 and a maximum drawdown of 13.4%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 3/10.
Top Market Events
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in...Industrial technology company Fortive NYSE:FTV reported Q2 CY2026 results , with sales up 7.Industrial technology company Fortive NYSE:FTV reported Q2 CY2026 results topping the market’s revenue expectations,...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 58.06
- MACD momentum is negative
- 30-day price change of -8.6%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 30.4 versus sector average of 33.2
- Trading below the 200-day average of 58.06
- Analyst targets imply +12.9% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 30.4 versus sector average of 33.2
- Analyst targets imply +12.9% versus the current price
- Dividend yield of 0.49%
Key Metrics & Analysis
Financial Health
Revenue Growth7.90%
Profit Margin12.38%
P/E Ratio30.4
ROE7.32%
ROA3.29%
Debt/Equity59.28
P/B Ratio2.8
Op. Cash Flow$1.1B
Free Cash Flow$939.1M
Industry P/E33.2
Technical Analysis
TrendNeutral
RSI36.6
Support$56.12
Resistance$62.63
MA 20$59.67
MA 50$60.65
MA 200$58.06
MACDBearish
VolumeIncreasing
Fear & Greed Index95.48
Valuation
Fair Value$44.33
Target Price$64.31
Upside/Downside12.94%
GradeFair
TypeGrowth
Dividend Yield0.49%
Risk Assessment
Beta0.64
Volatility29.72%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.